Equities research analysts expect Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings of $0.24 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.22 to $0.27. Diplomat Pharmacy posted earnings of $0.18 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 33.3%. The firm is expected to issue its next quarterly earnings report after the market closes on Monday, February 25th.
On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.81 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.84. For the next financial year, analysts anticipate that the company will post earnings of $0.86 per share, with EPS estimates ranging from $0.77 to $1.02. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Diplomat Pharmacy.
Several research firms have recently weighed in on DPLO. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 27th. ValuEngine downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, November 6th. William Blair downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. Robert W. Baird downgraded shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $22.00 to $10.00 in a research note on Wednesday, November 7th. Finally, Mizuho decreased their price target on shares of Diplomat Pharmacy to $18.00 and set a “neutral” rating on the stock in a research note on Friday, November 9th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $21.25.
DPLO traded up $0.32 during midday trading on Monday, hitting $13.42. 373,232 shares of the company traded hands, compared to its average volume of 648,846. The company has a quick ratio of 0.66, a current ratio of 0.95 and a debt-to-equity ratio of 0.58. The company has a market cap of $989.71 million, a price-to-earnings ratio of 15.98 and a beta of 0.98. Diplomat Pharmacy has a 52-week low of $12.30 and a 52-week high of $28.74.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.